Eclipse plans port-access TMR trial:
This article was originally published in Clinica
Executive Summary
Eclipse Surgical Technologies is planning a trial of minimally-invasive laser heart revascularisation, following approval from the FDA. Transmyocardial revascularisation (TMR) uses a laser to drill holes in the heart of patients with angina. Until now Eclipse had performed the procedure through a standard surgical chest incision. The development of a steerable fibreoptic laser catheter will allow the procedure to be performed via a 2-4 inch mini-thoracotomy.